Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

7.1K
Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
7.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.7K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.7K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Voltage-gated Ion Channels01:26

Voltage-gated Ion Channels

13.6K
Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
13.6K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

4.9K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Could NAPQI Contribute to Paracetamol Analgesia? Redox Modulation of Kv7 Ion Channels.

Pharmacology research & perspectives·2026
Same author

Decoding splicing variants in high-throughput sequencing: a functional validation approach integrating deep learning tools.

European journal of human genetics : EJHG·2026
Same author

Expanding the clinical spectrum of RNU4ATAC-opathies: more frequent and diverse than assumed.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

Functional and Molecular Characterization of Novel <i>GDF2 (BMP9</i>) and <i>BMP10</i> Variants From the French PAH and HHT Cohorts.

Circulation. Genomic and precision medicine·2026
Same author

Burst-Suppression EEG in Early Infantile Developmental and Epileptic Encephalopathies: Phenotype, Genotype, and Outcome.

Neurology·2026
Same author

Compound heterozygous SLC12A5 variants expand the molecular and functional spectrum of KCC2-developmental and epileptic encephalopathy.

Epilepsia·2026

Related Experiment Video

Updated: Apr 10, 2026

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

1.8K

Epilepsy-causing mutations in Kv7.2 C-terminus affect binding and functional modulation by calmodulin.

Paolo Ambrosino1, Alessandro Alaimo2, Silvia Bartollino1

  • 1Dept. of Medicine and Health Sciences, University of Molise, Campobasso, Italy.

Biochimica Et Biophysica Acta
|June 16, 2015
PubMed
Summary

Mutations in the KCNQ2 gene cause epilepsy by disrupting calmodulin binding to Kv7.2 channels. Modulating calmodulin shows potential for treating KCNQ2-related epilepsies.

Keywords:
CalmodulinElectrophysiologyEpilepsyFar-Western blottingFluorescenceKv7.2Surface Plasmon Resonance

More Related Videos

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

13.8K
Patch Clamp and Perfusion Techniques for Studying Ion Channels Expressed in Xenopus oocytes
10:19

Patch Clamp and Perfusion Techniques for Studying Ion Channels Expressed in Xenopus oocytes

Published on: January 10, 2011

22.0K

Related Experiment Videos

Last Updated: Apr 10, 2026

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

1.8K
Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

13.8K
Patch Clamp and Perfusion Techniques for Studying Ion Channels Expressed in Xenopus oocytes
10:19

Patch Clamp and Perfusion Techniques for Studying Ion Channels Expressed in Xenopus oocytes

Published on: January 10, 2011

22.0K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Mutations in the KCNQ2 gene lead to early-onset epilepsies, including Benign Familial Neonatal Seizures (BFNS).
  • The KCNQ2 gene encodes Kv7.2 potassium channel subunits, crucial for neuronal excitability.
  • Calmodulin (CaM) is a key regulator of Kv7.2 channel function.

Purpose of the Study:

  • To investigate how specific BFNS-causing mutations in KCNQ2 affect calmodulin binding and CaM-mediated channel regulation.
  • To elucidate the pathogenetic mechanisms underlying KCNQ2-related epilepsies at the molecular and functional levels.
  • To explore the therapeutic potential of modulating CaM-dependent Kv7.2 channel activity.

Main Methods:

  • Biochemical assays including Far-Western blotting, Surface Plasmon Resonance, and dansylated CaM fluorescence were used to assess CaM binding to wild-type and mutant Kv7.2 C-terminal fragments.
  • Electrophysiological recordings (patch-clamp) in CHO cells were performed to evaluate CaM-dependent regulation of Kv7.2 and Kv7.2/Kv7.3 currents in the presence of CaM or a CaM mutant.

Main Results:

  • Each KCNQ2 mutation exhibited distinct effects on CaM interaction and channel regulation.
  • Mutations ranged from causing minor CaM affinity changes with no functional impact (L351V) to significantly reduced CaM affinity and modulation (L351F, Y362C, R553Q).
  • One mutation (W344R) led to complete functional loss without altering CaM affinity, while CaM overexpression partially or fully restored function for some mutants, suggesting a therapeutic avenue.

Conclusions:

  • BFNS-causing KCNQ2 mutations result in specific molecular and functional deficits related to CaM interaction.
  • The varying impacts of mutations on CaM binding and regulation provide insights into the diverse phenotypes of KCNQ2-related epilepsies.
  • Enhancing CaM-dependent Kv7.2 channel modulation represents a promising therapeutic strategy for KCNQ2-related epilepsies.